Condensed Consolidated Statements Of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues:
Product sales, net	$ 338,754	$ 304,407	$ 977,895	$ 838,493
Royalties and contract revenues	2,118	2,177	6,027	6,240
Total revenues	340,872	306,584	983,922	844,733
Operating expenses:
Cost of product sales (excluding amortization and impairment of intangible assets)	28,385	26,994	78,496	88,610
Selling, general and administrative	104,044	93,501	323,564	300,420
Research and development	50,784	22,423	105,798	60,622
Acquired in-process research and development	0	75,000	0	202,000
Intangible asset amortization	26,127	30,630	74,472	94,607
Impairment charges	0	0	0	32,806
Total operating expenses	209,340	248,548	582,330	779,065
Income from operations	131,532	58,036	401,592	65,668
Interest expense, net	(12,650)	(14,530)	(44,707)	(36,035)
Foreign currency gain (loss)	(977)	6,483	(646)	6,680
Loss on extinguishment and modification of debt	0	0	(16,815)	0
Income before income tax provision	117,905	49,989	339,424	36,313
Income tax provision	29,945	24,221	92,651	60,598
Net income (loss)	87,960	25,768	246,773	(24,285)
Net income (loss) attributable to noncontrolling interests, net of tax	0	2	(1)	(1,060)
Net income (loss) attributable to Jazz Pharmaceuticals plc	$ 87,960	$ 25,766	$ 246,774	$ (23,225)
Net income (loss) attributable to Jazz Pharmaceuticals plc per ordinary share:
Basic (in dollars per share)	$ 1.43	$ 0.43	$ 4.04	$ (0.39)
Diluted (in dollars per share)	$ 1.39	$ 0.41	$ 3.91	$ (0.39)
Weighted-average ordinary shares used in per share calculation - basic (in shares)	61,435	60,305	61,145	59,457
Weighted-average ordinary shares used in per share calculation - diluted (in shares)	63,154	62,680	63,072	59,457